Antibody Information
General Information of This Antibody (ID: ANTI0JOGFB)
| Antibody Name | Anti-CDH3 antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | CDH3 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
BC3195 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible adults (≥18 y, ECOG 0-1) must have CDH3-expressing metastatic solid tumors, measurable lesions (RECIST 1.1), ≥3-month life expectancy, and adequate organ function. Exclusions include prior allogeneic transplants, uncontrolled hypertension, active CNS metastases, ocular/cardiac/pulmonary comorbidities, recent immunosuppression or CYP3A4 modulators, or pregnancy. Contraception is mandatory for 6 months post-treatment.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06548672 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase Ia/Ib, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients With Locally Advanced or Metastatic Solid Tumors
|
||||
| Primary Endpoint |
The study evaluates Dose Limiting Toxicities (DLTs) within the first 21 days of treatment to determine the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D). Incidence and severity of all Adverse Events (AEs) are monitored from screening through 12 weeks post-treatment.
|
||||
| Other Endpoint |
Efficacy is assessed via ORR, DCR, DoR, TTP, PFS (per RECIST 1.1), and OS (up to 100 months). Pharmacokinetics (AUC, Cmax, Tmax, t1/2, Vd, CL) are analyzed for BC3195 through 21 days post-last dose, alongside immunogenicity (ADA) monitoring for 30 days.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible participants (≥18 years, ECOG 0-1) must provide informed consent and have metastatic solid tumors refractory to standard therapies with ≥3-month life expectancy. Key exclusions include pregnancy, recent anticancer treatment, uncontrolled hypertension, active infections, cardiovascular disease, or poor compliance potential as judged by investigators. Effective contraception is required for 6 months post-treatment.
Click to Show/Hide
|
||||
| Administration Dosage |
BC3195 is administered as 1 hour (h) IV infusion every 3 weeks. An evaluation of seven dose levels (DLs) is planned: 0.3, 0.6, 1.2, 1.8, 2.4, 3.0 and 3.6 mg/kg with a BOIN design guiding dose escalation.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05957471 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase Ia/Ib, Open-Label, First-in-human, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BC3195 in Patients With Locally Advanced or Metastatic Solid Tumors
|
||||
| Primary Endpoint |
The trial will assess dose limiting toxicities (DLTs) observed during the first treatment cycle (21 days) to evaluate safety parameters.
|
||||
References